Twist Bioscience (Twist Bioscience) Retained Earnings

: $-1,076.2 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Twist Bioscience's retained earnings for the quarter that ended in Dec. 2023 was $-1,076.2 Mil.

Twist Bioscience's quarterly retained earnings declined from Jun. 2023 ($-986.8 Mil) to Sep. 2023 ($-1,033.0 Mil) and declined from Sep. 2023 ($-1,033.0 Mil) to Dec. 2023 ($-1,076.2 Mil).

Twist Bioscience's annual retained earnings declined from Sep. 2021 ($-610.6 Mil) to Sep. 2022 ($-828.4 Mil) and declined from Sep. 2022 ($-828.4 Mil) to Sep. 2023 ($-1,033.0 Mil).

Twist Bioscience Retained Earnings Historical Data

The historical data trend for Twist Bioscience's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Retained Earnings

-318.52

-458.46

-610.55

-828.42

-1,033.03

Twist Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings																-870.24	-929.40	-986.79	-1,033.03	-1,076.19

Twist Bioscience Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Twist Bioscience (NAS:TWST) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Twist Bioscience (Twist Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (NAS:TWST) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

0ME:Germany

Address

681 Gateway Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.twistbioscience.com

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Executives

Robert F. Werner	officer: Chief Accounting Officer	2500 FABER PLACE, PALO ALTO CA 94303
Dennis Cho	officer: See Remarks	C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Melissa A. Starovasnik	director	C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jan Johannessen	director	5555 NE MOORE CT., HILLSBORO OR 97124
William Banyai	director, officer: Chief Operating Officer	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Paula Green	officer: VP of Human Resources	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
James M Thorburn	officer: Chief Financial Officer	C/O ZILOG INC, 532 RACE STREET, SAN JOSE CA 95126
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Robert Chess	director
Patrick John Finn	officer: VP of Sales and Marketing	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Emily M. Leproust	director, officer: President & CEO	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Patrick Weiss	officer: VP of Operations	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Keith Crandell	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kevin Bruce Yankton	officer: Chief Accounting Officer	1678 S. PIONEER ROAD, SALT LAKE CITY UT 84104
Mark Daniels	officer: Chief Compliance Officer & GC	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158